AU2001288301A1 - Binding polypeptides and methods based thereon - Google Patents

Binding polypeptides and methods based thereon

Info

Publication number
AU2001288301A1
AU2001288301A1 AU2001288301A AU8830101A AU2001288301A1 AU 2001288301 A1 AU2001288301 A1 AU 2001288301A1 AU 2001288301 A AU2001288301 A AU 2001288301A AU 8830101 A AU8830101 A AU 8830101A AU 2001288301 A1 AU2001288301 A1 AU 2001288301A1
Authority
AU
Australia
Prior art keywords
methods based
binding polypeptides
polypeptides
binding
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001288301A
Inventor
James P. Beltzer
Tony L. Fleming
Daniel M. Potter
Craig A Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of AU2001288301A1 publication Critical patent/AU2001288301A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001288301A 2000-08-18 2001-08-17 Binding polypeptides and methods based thereon Abandoned AU2001288301A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22670000P 2000-08-18 2000-08-18
US60/226,700 2000-08-18
PCT/US2001/025850 WO2002016411A2 (en) 2000-08-18 2001-08-17 Binding polypeptides and methods based thereon

Publications (1)

Publication Number Publication Date
AU2001288301A1 true AU2001288301A1 (en) 2002-03-04

Family

ID=22850040

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001288301A Abandoned AU2001288301A1 (en) 2000-08-18 2001-08-17 Binding polypeptides and methods based thereon

Country Status (3)

Country Link
US (4) US20030091565A1 (en)
AU (1) AU2001288301A1 (en)
WO (1) WO2002016411A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
EP2281843B1 (en) * 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
AU2001288301A1 (en) * 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
MXPA03010210A (en) 2001-05-11 2004-03-10 Amgen Inc Peptides and related molecules that bind to tall-1.
US20020150579A1 (en) * 2002-01-10 2002-10-17 Kimberly Robert P. B lymphocyte stimulator (BLyS) as a marker in management of systemic lupus erythematosus
CA2505843A1 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
US8512971B2 (en) * 2002-12-10 2013-08-20 Echelon Biosciences, Inc. Compounds and methods of use thereof for assaying lysophospholipase D activity
US7144590B2 (en) * 2003-01-09 2006-12-05 Lipoprotein Technologies, Inc. Bioactive compositions derived from humulus lupulus
WO2004074511A1 (en) * 2003-02-21 2004-09-02 Garvan Institute Of Medical Research Diagnosis and treatment of baff-mediated autoimmune diseases and cancer
EP1629001A2 (en) * 2003-06-05 2006-03-01 Genentech, Inc. Blys antagonists and uses thereof
CA2596276A1 (en) * 2005-01-28 2006-08-03 Biogen Idec Ma Inc. Use of baff to treat th2-mediated conditions
CA2605143A1 (en) 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2626082C (en) * 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
WO2009009045A2 (en) * 2007-07-10 2009-01-15 The Scripps Research Institute Escape libraries of target polypeptides
US8183342B2 (en) * 2007-11-06 2012-05-22 Case Western Reserve University Method of treating chemotherapy-induced thrombocytopenia
AU2009204472A1 (en) * 2008-01-04 2009-07-16 Biotrofix, Inc. Methods and compositions for non-covalently enhanced receptor binding
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
US9493545B2 (en) 2009-02-11 2016-11-15 Albumedix A/S Albumin variants and conjugates
US20110014190A1 (en) * 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
JP5566374B2 (en) * 2009-04-10 2014-08-06 国立大学法人大阪大学 Drugs for diseases that cause neoplastic growth of plasma cells
US8748380B2 (en) 2009-10-30 2014-06-10 Novozymes Biopharma Dk A/S Albumin variants
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
EP2578681B1 (en) * 2010-05-24 2015-07-01 Kagoshima University Iga-binding peptide and iga purification using same
US20110311548A1 (en) * 2010-06-18 2011-12-22 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system
EP2705051A1 (en) * 2011-05-05 2014-03-12 Novozymes Biopharma DK A/S Albumin variants
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
AU2013234299B2 (en) 2012-03-16 2017-06-22 Albumedix Ltd. Albumin variants
MX2015005363A (en) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Albumin variants.
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (en) 2013-03-13 2021-08-17 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
ES2731232T3 (en) 2013-03-15 2019-11-14 Inst Nat Sante Rech Med Method and pharmaceutical composition for use in the treatment and prediction of myocardial infarction
US20160331853A1 (en) * 2014-01-21 2016-11-17 The Trustees Of Columbia University In The City Of New York Compositions for radiotherapy and uses thereof
TWI567971B (en) 2014-04-22 2017-01-21 友達光電股份有限公司 Light emitting device
AR104368A1 (en) 2015-04-03 2017-07-19 Lilly Co Eli ANTI-CD20- / ANTI-BAFF BIESPECTIFIC ANTIBODIES
WO2017003908A1 (en) 2015-06-30 2017-01-05 The Trustees Of Columbia University In The City Of New York Talc-bound compositions and uses thereof
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
SG11202113046PA (en) * 2019-05-24 2021-12-30 Avitide LLC Affinity agents

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8923843D0 (en) * 1989-10-23 1989-12-13 Salutar Inc Compounds
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5635384A (en) * 1990-06-11 1997-06-03 Dowelanco Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5962301A (en) * 1992-06-12 1999-10-05 Massachusetts Institute Of Technology Relatedness of human interleukin-1β convertase gene to a C. elegans cell death gene, inhibitory portions of these genes and uses therefor
JPH08501085A (en) * 1992-08-26 1996-02-06 プレジデント アンド フェローズ オブ ハーバード カレッジ Use of cytokine IP-10 as an antitumor agent
US5605671A (en) * 1992-10-05 1997-02-25 The Regents Of The University Of Michigan Radiolabeled neutrophil activating peptides for imaging
US5869331A (en) * 1992-11-20 1999-02-09 University Of Medicine & Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
WO1994020540A1 (en) 1993-03-02 1994-09-15 Universidad De Valladolid NON-TOXIC RIBOSOME INACTIVATING PROTEINS (RIPs) WITH TWO CHAINS, PROCESS FOR THE PREPARATION THEREOF AND APPLICATIONS
AU7694594A (en) 1993-09-06 1995-03-27 Menarini Ricerche Sud S.P.A. Ribosome inactivating proteins extracted from seeds of saponaria ocymoides and vaccaria pyramidata, their preparation and immunotoxins containing them
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5597709A (en) 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
US5817485A (en) 1994-03-08 1998-10-06 Human Genome Sciences, Inc. Nucleic acids and cells for recombinant production of fibroblast growth factor-10
US5633147A (en) 1994-03-08 1997-05-27 Human Genome Sciences, Inc. Transforming growth factor αH1
JPH10500301A (en) 1994-05-16 1998-01-13 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Macrophage migration inhibitory factor-3
KR100507431B1 (en) 1994-11-07 2005-12-21 휴먼 게놈 사이언시즈, 인코포레이티드 Tumor Necorsis Factor-γ
JPH11507205A (en) 1995-04-27 1999-06-29 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド Human tumor necrosis factor receptor
US5874409A (en) * 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
JP2001501453A (en) 1996-03-14 2001-02-06 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Human tumor necrosis factor δ and ε
US6541224B2 (en) * 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
EP0904278A4 (en) 1996-03-22 1999-09-15 Human Genome Sciences Inc Apoptosis inducing molecule ii
EP0954531A1 (en) 1996-06-06 1999-11-10 Lajolla Pharmaceutical Company aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
IT1286663B1 (en) 1996-06-27 1998-07-15 Ministero Uni Ricerca Scient E PROTEIN CAPABLE OF INHIBITING RIBOSOMIAL ACTIVITY, ITS PREPARATION AND USE AS A CHEMICAL OR RECOMBINANT IMMUNOCONUGATE AND SEQUENCE OF CDNA
ES2316153T3 (en) 1996-08-16 2009-04-01 Human Genome Sciences, Inc. HUMAN ALFA ENDOQUINA.
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US20020115112A1 (en) * 1999-02-23 2002-08-22 Human Genome Sciences, Inc. Neutrokine-alpha and Neutrokine-alpha splice variant
US20030175208A1 (en) * 1996-10-25 2003-09-18 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
KR20050004269A (en) 1996-10-25 2005-01-12 휴먼 게놈 사이언시즈, 인코포레이티드 Neutrokine alpha
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6689579B1 (en) * 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
EP1798288B1 (en) * 1997-05-07 2009-09-16 Schering Corporation Human Toll-like receptor proteins, related reagents and methods
EP0975762B1 (en) 1997-06-06 2011-10-05 PanGenetics B.V. Type-1 ribosome-inactivating protein
IL133315A0 (en) 1997-06-06 2001-04-30 Regeneron Pharma Ntn-2 member of tnf ligand family
CA2292899A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
US5948619A (en) * 1997-07-31 1999-09-07 Incyte Pharmaceuticals, Inc. Human zygin-1
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US5795724A (en) * 1997-09-12 1998-08-18 Incyte Pharmaceuticals, Inc. Human N-acetyl transferase
PL339740A1 (en) 1997-09-12 2001-01-02 Biogen Kay - a novel immune system protein
US20020055624A1 (en) * 1997-11-17 2002-05-09 Steven R. Wiley Tnf-delta ligand and uses thereof
US20010010925A1 (en) * 1997-11-17 2001-08-02 Steven R. Wiley Methods of detecting target nucleic acids of tnf-delta
CA2310987A1 (en) 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
AU2212299A (en) 1998-01-05 1999-07-26 Genentech Inc. Compositions and methods for the treatment of tumor
WO1999046295A1 (en) * 1998-03-12 1999-09-16 Shanghai Second Medical University A gene homologous to the drosophila b(2)gen gene and putative yeast 26.5kd protein ypr015c
AU1467000A (en) 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) * 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
WO2000040716A2 (en) 1999-01-07 2000-07-13 Zymogenetics, Inc. Soluble receptor br43x2 and methods of using them for therapy
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
EP2974736A1 (en) 1999-01-25 2016-01-20 Biogen MA Inc. Baff, inhibitors thereof and their use in the modulation of the b-cell response
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
AU2880400A (en) 1999-02-12 2000-08-29 Amgen, Inc. Tnf-related proteins
CA2363112A1 (en) 1999-02-23 2000-08-31 Craig A. Rosen Neutrokine-alpha and neutrokine-alpha splice variant
WO2000077256A1 (en) 1999-06-11 2000-12-21 Human Genome Sciences, Inc. 48 human secreted proteins
WO2000058362A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
US20030022233A1 (en) * 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
MXPA02001665A (en) 1999-08-17 2003-07-14 Biogen Inc Baff receptor (bcma), an immunoregulatory agent.
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
EP1690872A3 (en) 1999-12-01 2006-08-23 Genentech, Inc. Composition and methods for the diagnosis of tumours
AU3495301A (en) * 2000-02-11 2001-08-20 Biogen Inc Heterologous polypeptide of the tnf family
DE60028830T2 (en) 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco ANTI-APRIL ANTIBODIES AND HYBRIDOMA CELLS
AU2001253920B2 (en) 2000-04-27 2006-03-16 Apoxis Sa Use of taci as an anti-tumor agent
CA2408617A1 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
EP2281843B1 (en) * 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
JP2004512262A (en) * 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション Non-radioactive anti-CD20 antibody / radiolabeled anti-CD22 antibody combination
EP1309718A4 (en) 2000-08-15 2004-08-25 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
EP1339746A2 (en) * 2000-08-18 2003-09-03 Dyax Corp. Binding polypeptides for b lymphocyte stimulator protein (blys)
AU2001288301A1 (en) * 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
ATE432986T1 (en) 2000-11-07 2009-06-15 Zymogenetics Inc HUMAN RECEPTOR FOR TUMOR NECROSIS FACTOR
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
MXPA03010210A (en) * 2001-05-11 2004-03-10 Amgen Inc Peptides and related molecules that bind to tall-1.
KR20040030628A (en) 2001-05-24 2004-04-09 지모제넥틱스, 인코포레이티드 Taci-immunoglobulin fusion proteins
AR035119A1 (en) 2001-08-16 2004-04-14 Lilly Co Eli ANTI-HTNFSF13B HUMAN ANTI-BODIES
JP4002082B2 (en) * 2001-09-14 2007-10-31 古河電気工業株式会社 Optical fiber preform and manufacturing method thereof
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
CA2476675A1 (en) 2001-10-17 2003-04-24 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
MXPA04004266A (en) 2001-11-06 2004-07-08 Lilly Co Eli Use of il-19, il-22 and il-24 to treat hematopoietic disorders.
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US20020150579A1 (en) * 2002-01-10 2002-10-17 Kimberly Robert P. B lymphocyte stimulator (BLyS) as a marker in management of systemic lupus erythematosus
US20080267965A1 (en) * 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
AU2003299819A1 (en) 2002-12-23 2004-07-22 Human Genome Sciences, Inc. Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
WO2004074511A1 (en) 2003-02-21 2004-09-02 Garvan Institute Of Medical Research Diagnosis and treatment of baff-mediated autoimmune diseases and cancer
EP1629001A2 (en) 2003-06-05 2006-03-01 Genentech, Inc. Blys antagonists and uses thereof
BRPI0415709A (en) 2003-10-20 2006-12-19 Biogen Idec Inc therapeutic regimens for baff antagonists
CA2596276A1 (en) * 2005-01-28 2006-08-03 Biogen Idec Ma Inc. Use of baff to treat th2-mediated conditions
RU2393874C2 (en) * 2005-02-01 2010-07-10 Рисерч Дивелопмент Фаундейшн Polypeptides of directed action
US20090215071A1 (en) * 2005-07-28 2009-08-27 Teresa Cachero Methods of targeting baff
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease

Also Published As

Publication number Publication date
WO2002016411A2 (en) 2002-02-28
WO2002016411A3 (en) 2003-09-25
US8062906B2 (en) 2011-11-22
US20030091565A1 (en) 2003-05-15
US20070293434A9 (en) 2007-12-20
US20100144058A1 (en) 2010-06-10
US20060084608A1 (en) 2006-04-20
US20120022006A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
AU2001288301A1 (en) Binding polypeptides and methods based thereon
AU3633000A (en) Neutrokine-alpha binding proteins and methods based thereon
AU2002322477A1 (en) Composite binding polypeptides
AU2001271744A1 (en) Leucine-rich repeat proteins, zlrr7, zlrr8 and zlrr9
AU2002246502A1 (en) Nucleic acids and polypeptides
AU2001292561A1 (en) Nucleic acids and polypeptides
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2190801A (en) Binding protein
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU2000275748A1 (en) Hla-a2.1 binding peptides and their uses
AU2001288220A1 (en) Hyperglycosylated polypeptides
AU2002341828A1 (en) Enhanced proteins and methods for their use
AU2136401A (en) P450rai-2 and related proteins
AU2002256556A1 (en) Sea-trosy and related methods
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
AU2565100A (en) Methods and compositions using binding partners
AU2002239747A1 (en) Cystoskeleton-associated proteins
EP1142616A3 (en) Snowboardbinding and a boot for such a binding
AU2002218199A1 (en) Truncated phosphodiesterase-7 polypeptides
AU2000274739A1 (en) Hla binding peptides and their uses
AU2001294267A1 (en) Survivin-like polypeptides and dnas thereof
AU2001274563A1 (en) Novel polypeptide and its dna
AU2001251181A1 (en) Homeobox binding sites and their uses
AU2002227496A1 (en) Polynucleotides and polypeptides
AU2001243425A1 (en) Presenilin/crk binding polypeptides (pcbp) and methods of use thereof